All In Biotech

Drug Trial Radar · NCT04586023

Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS)

A Phase III Multicenter Randomized, Double-blind, Double-dummy, Parallel-group Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Adult Patients With Relapsing Multiple Sclerosis

Last checked: Nov 19, 2026Latest source record: Sep 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 751 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

751

Actual

Start

Mar 24, 2021

Primary completion

Sep 5, 2025

Study completion Jul 9, 2027

Sponsor

Lead sponsor
Hoffmann-La RocheRoche (Genentech) (RHHBY)
Sponsor type
Industry
First posted
Oct 14, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A study to evaluate the efficacy and safety of fenebrutinib on disability progression and relapse rate in adult participants with RMS. Eligible participants will be randomized in a 1:1 ratio to receive either fenebrutinib or teriflunomide. At the end of the double-blind treatment (DBT) phase (after disclosure of the DBT results), the Sponsor will determine whether or not to initiate the open-label extension (OLE) phase of the study.

Conditions

  • Relapsing Multiple Sclerosis

Interventions

  • FenebrutinibDrug

    Participants will receive fenebrutinib.

  • TeriflunomideDrug

    Participants will receive teriflunomide.

  • PlaceboDrug

    Participants will receive teriflunomide-matching placebo or fenebrutinib-matching placebo.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Annualized Relapse Rate (ARR)Time frame: Minimum of 96 weeks

Locations

106 sites in 17 countries. Site status is shown where the registry gives one.

  • North Central Neurology Associates

    Cullman, Alabama

  • Xenoscience

    Phoenix, Arizona

  • Los Angeles Biomedical Research Institute at Harbor-UCLA

    Torrance, California

  • Georgetown University Medical Center

    Washington D.C., District of Columbia

  • University of South Florida

    Tampa, Florida

  • American Health Network Institute, LLC

    Avon, Indiana

  • University of Kansas Medical Center

    Kansas City, Kansas

  • Neuro Institute of New England P.C.

    Foxborough, Massachusetts

  • University of Cincinnati

    Cincinnati, Ohio

  • Hope Neurology

    Knoxville, Tennessee

  • Integrated Neurology Services PLLC

    Falls Church, Virginia

  • Medical College of Wisconsin, Inc.

    Milwaukee, Wisconsin

  • Kepler Universitätskliniken GmbH - Med Campus III

    Linz, Austria

  • Jordy Sinapse Medicina LTDA ME

    São Paulo, Brazil

  • L2 Ip Instituto de Pesquisas Clinicas Ltda ME

    Brasília, Federal District, Brazil

  • Freire Pesquisa Clinica

    Belo Horizonte, Minas Gerais, Brazil

  • Instituto de Neurologia de Curitiba

    Curitiba, Paraná, Brazil

  • IMV Pesquisa Neurológica

    Porto Alegre, Rio Grande do Sul, Brazil

  • Núcleo de Pesquisa do Rio Grande do Sul

    Porto Alegre, Rio Grande do Sul, Brazil

  • Hospital Sao Lucas - PUCRS

    Porto Alegre, Rio Grande do Sul, Brazil

  • Clinica Neurologica

    Joinville, Santa Catarina, Brazil

  • Praxis Pesquisa Médica

    Santo André, São Paulo, Brazil

  • CEMEC - Centro Multidisciplinar de Estudos Clínicos

    São Bernardo do Campo, São Paulo, Brazil

  • Centro de Pesquisas Clinicas

    São Paulo, São Paulo, Brazil

  • Hospital Santa Marcelina

    São Paulo, São Paulo, Brazil

  • UMHAT Dr. Georgi Stranski

    Pleven, Bulgaria

  • MHATNP Sveti Naum EAD

    Sofia, Bulgaria

  • University of Alberta Hospital

    Edmonton, Alberta, Canada

  • The Ottawa Hospital - General Campus

    Ottawa, Ontario, Canada

  • CIUSSS du Saguenay Lac-Saint-Jean, Chicoutimi Hospital

    Chicoutimi, Quebec, Canada

  • MUCH - Montreal Neurological Institute & Hospital

    Montreal, Quebec, Canada

  • CHU de Québec

    Québec, Quebec, Canada

  • Sydvestjysk Sygehus Esbjerg

    Esbjerg, Denmark

  • Hjerne- og nervesygdomme, Ambulatorium, Skleroseklinikken

    Sønderborg, Denmark

  • Hopital Gabriel Montpied CHU de Clermont-Ferrand

    Clermont-Ferrand, France

  • Hôpital Pasteur

    Nice, France

  • Hôpital Charles Nicolle

    Rouen, France

  • CHU toulouse - Hôpital Purpan

    Toulouse, France

  • Hospital Eginition

    Athens, Greece

  • University General Hospital of Larisa

    Larissa, Greece

Showing 40 of 106 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.